In certain embodiments, any controlled release otic formulation described herein increases the exposure of a therapeutic agent and increases the length of time that the concentration of a therapeutic agent is above C min by about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or about 90% compared to a formulation or composition that is not a controlled release otic formulation or composition
In a mouse model of KA-triggered seizure, it was also validated that lapatinib blocked GPX4-dependent ferroptosis
Up to half of people prescribed a GLP-1 stop taking it by one year, and 85% stop by two years
600 mg of black maca: among the highest dosages in the category
Manufacturing Capability Our manufacturing infrastructure is designed to meet the stringent demands of pharmaceutical production, with state-of-the-art facilities compliant with current Good Manufacturing Practices (cGMP)